ReviewJournal of translational medicine2026
MTHFD2: a promising metabolic checkpoint for diseases.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Three Anthelmintics on the Transcriptome of FHs 74 Int Enterocytes.Tropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMTHFD2, a critical enzyme in one-carbon metabolism, regulates cellular growth, redox balance, and energy homeostasis. Aberrant MTHFD2 expression has been implicated in the pathogenesis and progression of various diseases. MTHFD2 is a promising therapeutic target, however, its roles in diseases and upstream and downstream regulatory mechanisms have not been clarified.
methodsThis study reviewed literature from databases such as PubMed and Google Scholar, using keywords "MTHFD2", aiming to summarize current research on the functions and mechanisms of MTHFD2 on diseases and provide theoretical support for future investigation of related therapeutic strategies.
resultsHigh expression of MTHFD2 promotes cancer progression and MTHFD2 can be used as a sensitization target in cancer treatment. MTHFD2 influences tumor microenvironment through disturbing immune cell infiltration and immune checkpoints expression. Aberrant MTHFD2 expression can also participate in other diseases. Consequently, a range of MTHFD2 inhibitors has been developed, advancing to both preclinical and clinical evaluations.
conclusionsThis review examines the multifaceted roles of MTHFD2 in cancer biology and other pathological conditions, describing its influence on the tumor microenvironment and relevance in immunotherapeutic applications. Structural strategies for MTHFD2 inhibitor development are explored, alongside challenges and opportunities for leveraging MTHFD2 as a diagnostic, therapeutic, and prognostic target in disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.